BioTech Medical to distribute SpectraSan 24 silver dihydrogen citrate disinfectants
Pure Bioscience has agreed that BioTech Medical can distribute its silver dihydrogen citrate (SDC)-based disinfectant under the name SpectraSan24. The agreement also grants BioTech Medical rights to market Pure’s Cruise Control product, which provides 24-hour protection against Norovirus, to the cruise line industry.
SpectraSan24 is a Category IV antimicrobial for which precautionary labelling statements are not required. Currently undergoing registration in the US, it is said to carry a 30-second kill time on standard indicator bacteria, a 24-hour residual kill on standard indicator bacteria, a two-minute kill time on some resistant strains of bacteria, 10-minute kill time on fungi, 30-second kill time on HIV Type I, and 10-minute kill time on other pathogenic viruses.
Andrea L Goren, executive director of BioTech Medical, said: "BioTech Medical is committed to delivering innovative and environmentally responsible technologies to address significant public health threats. We are thrilled to be able to integrate SpectraSan24 into our business to benefit the global community."
Michael L Krall, president and ceo of Pure Bioscience, added: "BioTech Medical has a long and lucrative track record of marketing healthcare products, especially disruptive technologies like SDC. BioTech Medical's marketing team deploys a structured programme to introduce and sell pioneering products, and we believe its strategy will result in near-term market penetration of SpectraSan24 in a variety of industries."